- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- Breast cancer
- CNS cancers
- Colorectal and other GI cancers
- Gynecologic Cancers
- Leukemias, lymphomas, and other hematologic cancers
- Pancreatic, thyroid, and other endocrine cancers
- Respiratory and thoracic cancers
Bladder, kidney, and other urologic cancers:
Indications for: Doxorubicin HCl Solution
Disseminated neoplasias (eg, bladder carcinoma, Wilms' tumor).
Adults and Children:
Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.
Doxorubicin HCl Solution Contraindications:
Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.
Boxed Warning:
Cardiomyopathy. Secondary malignancies. Extravasation and tissue necrosis. Severe myelosuppression.
Doxorubicin HCl Solution Warnings/Precautions:
Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart disease or risk thereof. Obtain CBCs, bilirubin, SGOT/SGPT, creatinine, LVEF prior to and during therapy. Monitor cardiac function (eg, MUGA, echocardiogram), blood uric acid levels, potassium, calcium, and phosphate after initiation. Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity (avoid during 1st trimester). Advise to use effective contraception during and for 6 months (females) and 3 months (males w. female partners) after the last dose. Males w. pregnant partners should use condoms during for ≥10 days after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 10 days after the last dose).
See Also:
Doxorubicin HCl Solution Classification:
Anthracycline.
Doxorubicin HCl Solution Interactions:
See Contraindications. Avoid concomitant inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. Mediastinal irradiation, cyclophosphamide, other anthracyclines increase risk of cardiac toxicity. May increase toxicity of cyclophosphamide, mercaptopurine. Avoid dexrazoxane (during initiation), trastuzumab (for up to 7 months). Doxorubicin toxicity increased if given after paclitaxel infusion (give doxorubicin dose first).
Adverse Reactions:
Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.
How Supplied:
Contact supplier.
Bone and connective tissue cancer:
Indications for: Doxorubicin HCl Solution
Disseminated neoplasias (eg, soft tissue and bone sarcomas).
Adults and Children:
Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.
Doxorubicin HCl Solution Contraindications:
Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.
Boxed Warning:
Cardiomyopathy. Secondary malignancies. Extravasation and tissue necrosis. Severe myelosuppression.
Doxorubicin HCl Solution Warnings/Precautions:
Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart disease or risk thereof. Obtain CBCs, bilirubin, SGOT/SGPT, creatinine, LVEF prior to and during therapy. Monitor cardiac function (eg, MUGA, echocardiogram), blood uric acid levels, potassium, calcium, and phosphate after initiation. Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity (avoid during 1st trimester). Advise to use effective contraception during and for 6 months (females) and 3 months (males w. female partners) after the last dose. Males w. pregnant partners should use condoms during for ≥10 days after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 10 days after the last dose).
See Also:
Doxorubicin HCl Solution Classification:
Anthracycline.
Doxorubicin HCl Solution Interactions:
See Contraindications. Avoid concomitant inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. Mediastinal irradiation, cyclophosphamide, other anthracyclines increase risk of cardiac toxicity. May increase toxicity of cyclophosphamide, mercaptopurine. Avoid dexrazoxane (during initiation), trastuzumab (for up to 7 months). Doxorubicin toxicity increased if given after paclitaxel infusion (give doxorubicin dose first).
Adverse Reactions:
Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.
How Supplied:
Contact supplier.
Breast cancer:
Indications for: Doxorubicin HCl Solution
Disseminated neoplasias (eg, breast carcinoma). Adjunct in breast cancer after resection.
Adults and Children:
Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.
Doxorubicin HCl Solution Contraindications:
Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.
Boxed Warning:
Cardiomyopathy. Secondary malignancies. Extravasation and tissue necrosis. Severe myelosuppression.
Doxorubicin HCl Solution Warnings/Precautions:
Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart disease or risk thereof. Obtain CBCs, bilirubin, SGOT/SGPT, creatinine, LVEF prior to and during therapy. Monitor cardiac function (eg, MUGA, echocardiogram), blood uric acid levels, potassium, calcium, and phosphate after initiation. Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity (avoid during 1st trimester). Advise to use effective contraception during and for 6 months (females) and 3 months (males w. female partners) after the last dose. Males w. pregnant partners should use condoms during for ≥10 days after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 10 days after the last dose).
See Also:
Doxorubicin HCl Solution Classification:
Anthracycline.
Doxorubicin HCl Solution Interactions:
See Contraindications. Avoid concomitant inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. Mediastinal irradiation, cyclophosphamide, other anthracyclines increase risk of cardiac toxicity. May increase toxicity of cyclophosphamide, mercaptopurine. Avoid dexrazoxane (during initiation), trastuzumab (for up to 7 months). Doxorubicin toxicity increased if given after paclitaxel infusion (give doxorubicin dose first).
Adverse Reactions:
Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.
How Supplied:
Contact supplier.
CNS cancers:
Indications for: Doxorubicin HCl Solution
Disseminated neoplasias (eg, neuroblastoma).
Adults and Children:
Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.
Doxorubicin HCl Solution Contraindications:
Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.
Boxed Warning:
Cardiomyopathy. Secondary malignancies. Extravasation and tissue necrosis. Severe myelosuppression.
Doxorubicin HCl Solution Warnings/Precautions:
Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart disease or risk thereof. Obtain CBCs, bilirubin, SGOT/SGPT, creatinine, LVEF prior to and during therapy. Monitor cardiac function (eg, MUGA, echocardiogram), blood uric acid levels, potassium, calcium, and phosphate after initiation. Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity (avoid during 1st trimester). Advise to use effective contraception during and for 6 months (females) and 3 months (males w. female partners) after the last dose. Males w. pregnant partners should use condoms during for ≥10 days after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 10 days after the last dose).
See Also:
Doxorubicin HCl Solution Classification:
Anthracycline.
Doxorubicin HCl Solution Interactions:
See Contraindications. Avoid concomitant inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. Mediastinal irradiation, cyclophosphamide, other anthracyclines increase risk of cardiac toxicity. May increase toxicity of cyclophosphamide, mercaptopurine. Avoid dexrazoxane (during initiation), trastuzumab (for up to 7 months). Doxorubicin toxicity increased if given after paclitaxel infusion (give doxorubicin dose first).
Adverse Reactions:
Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.
How Supplied:
Contact supplier.
Colorectal and other GI cancers:
Indications for: Doxorubicin HCl Solution
Disseminated neoplasias (eg, gastric carcinoma).
Adults and Children:
Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.
Doxorubicin HCl Solution Contraindications:
Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.
Boxed Warning:
Cardiomyopathy. Secondary malignancies. Extravasation and tissue necrosis. Severe myelosuppression.
Doxorubicin HCl Solution Warnings/Precautions:
Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart disease or risk thereof. Obtain CBCs, bilirubin, SGOT/SGPT, creatinine, LVEF prior to and during therapy. Monitor cardiac function (eg, MUGA, echocardiogram), blood uric acid levels, potassium, calcium, and phosphate after initiation. Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity (avoid during 1st trimester). Advise to use effective contraception during and for 6 months (females) and 3 months (males w. female partners) after the last dose. Males w. pregnant partners should use condoms during for ≥10 days after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 10 days after the last dose).
See Also:
Doxorubicin HCl Solution Classification:
Anthracycline.
Doxorubicin HCl Solution Interactions:
See Contraindications. Avoid concomitant inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. Mediastinal irradiation, cyclophosphamide, other anthracyclines increase risk of cardiac toxicity. May increase toxicity of cyclophosphamide, mercaptopurine. Avoid dexrazoxane (during initiation), trastuzumab (for up to 7 months). Doxorubicin toxicity increased if given after paclitaxel infusion (give doxorubicin dose first).
Adverse Reactions:
Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.
How Supplied:
Contact supplier.
Gynecologic Cancers:
Leukemias, lymphomas, and other hematologic cancers:
Indications for: Doxorubicin HCl Solution
Disseminated neoplasias (eg, acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin's disease, malignant lymphoma).
Adults and Children:
Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.
Doxorubicin HCl Solution Contraindications:
Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.
Boxed Warning:
Cardiomyopathy. Secondary malignancies. Extravasation and tissue necrosis. Severe myelosuppression.
Doxorubicin HCl Solution Warnings/Precautions:
Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart disease or risk thereof. Obtain CBCs, bilirubin, SGOT/SGPT, creatinine, LVEF prior to and during therapy. Monitor cardiac function (eg, MUGA, echocardiogram), blood uric acid levels, potassium, calcium, and phosphate after initiation. Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity (avoid during 1st trimester). Advise to use effective contraception during and for 6 months (females) and 3 months (males w. female partners) after the last dose. Males w. pregnant partners should use condoms during for ≥10 days after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 10 days after the last dose).
See Also:
Doxorubicin HCl Solution Classification:
Anthracycline.
Doxorubicin HCl Solution Interactions:
See Contraindications. Avoid concomitant inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. Mediastinal irradiation, cyclophosphamide, other anthracyclines increase risk of cardiac toxicity. May increase toxicity of cyclophosphamide, mercaptopurine. Avoid dexrazoxane (during initiation), trastuzumab (for up to 7 months). Doxorubicin toxicity increased if given after paclitaxel infusion (give doxorubicin dose first).
Adverse Reactions:
Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.
How Supplied:
Contact supplier.
Pancreatic, thyroid, and other endocrine cancers:
Indications for: Doxorubicin HCl Solution
Disseminated neoplasias (eg, thyroid carcinoma).
Adults and Children:
Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.
Doxorubicin HCl Solution Contraindications:
Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.
Boxed Warning:
Cardiomyopathy. Secondary malignancies. Extravasation and tissue necrosis. Severe myelosuppression.
Doxorubicin HCl Solution Warnings/Precautions:
Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart disease or risk thereof. Obtain CBCs, bilirubin, SGOT/SGPT, creatinine, LVEF prior to and during therapy. Monitor cardiac function (eg, MUGA, echocardiogram), blood uric acid levels, potassium, calcium, and phosphate after initiation. Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity (avoid during 1st trimester). Advise to use effective contraception during and for 6 months (females) and 3 months (males w. female partners) after the last dose. Males w. pregnant partners should use condoms during for ≥10 days after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 10 days after the last dose).
See Also:
Doxorubicin HCl Solution Classification:
Anthracycline.
Doxorubicin HCl Solution Interactions:
See Contraindications. Avoid concomitant inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. Mediastinal irradiation, cyclophosphamide, other anthracyclines increase risk of cardiac toxicity. May increase toxicity of cyclophosphamide, mercaptopurine. Avoid dexrazoxane (during initiation), trastuzumab (for up to 7 months). Doxorubicin toxicity increased if given after paclitaxel infusion (give doxorubicin dose first).
Adverse Reactions:
Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.
How Supplied:
Contact supplier.
Respiratory and thoracic cancers:
Indications for: Doxorubicin HCl Solution
Disseminated neoplasias (eg, bronchogenic carcinoma).
Adults and Children:
Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.
Doxorubicin HCl Solution Contraindications:
Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.
Boxed Warning:
Cardiomyopathy. Secondary malignancies. Extravasation and tissue necrosis. Severe myelosuppression.
Doxorubicin HCl Solution Warnings/Precautions:
Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart disease or risk thereof. Obtain CBCs, bilirubin, SGOT/SGPT, creatinine, LVEF prior to and during therapy. Monitor cardiac function (eg, MUGA, echocardiogram), blood uric acid levels, potassium, calcium, and phosphate after initiation. Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity (avoid during 1st trimester). Advise to use effective contraception during and for 6 months (females) and 3 months (males w. female partners) after the last dose. Males w. pregnant partners should use condoms during for ≥10 days after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 10 days after the last dose).
See Also:
Doxorubicin HCl Solution Classification:
Anthracycline.
Doxorubicin HCl Solution Interactions:
See Contraindications. Avoid concomitant inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. Mediastinal irradiation, cyclophosphamide, other anthracyclines increase risk of cardiac toxicity. May increase toxicity of cyclophosphamide, mercaptopurine. Avoid dexrazoxane (during initiation), trastuzumab (for up to 7 months). Doxorubicin toxicity increased if given after paclitaxel infusion (give doxorubicin dose first).
Adverse Reactions:
Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.
How Supplied:
Contact supplier.
